Skip to main content

Select Drug Profiles

Conference Highlights ASH
Improving the Standard of Care
R. Donald Harvey, PharmD, FCCP, BCOP
Read More
Perspectives
PEACE Time
David B. Nash, MD, MBA
Read More
Letters to the Editor
Correspondence: Cost of Treatment for Relapsed/Refractory Multiple Myeloma
Read More
Original Research, Practice Management
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
Lisa M. Bloudek, PharmD, MS, Dinara Makenbaeva, MD, MBA, Michael Eaddy, PharmD, PhD
Stakeholder Perspective
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
by Gary Branning, MBA
Read More
Original Research
The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice
Norman E. Lepor, MD, Dean J. Kereiakes, MD
Read More
Perspectives
Employers Engaged in Benefit Design Innovation: Long-Term Trends in a 2015 National Survey
Cheryl Larson, F. Randy Vogenberg, PhD, FASHP
Read More
Original Research
Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis
Joseph Tkacz, MS, Michael P. Ingham, MSc, Brenna L. Brady, PhD, Roxanne Meyer, PharmD, Charles Ruetsch, PhD
Stakeholder Perspective
You Cannot Manage What You Cannot Measure
by Sharon Glave Frazee, PhD, MPH
Read More
FDA Approvals, In the News
FDA Approves First Seasonal Influenza Vaccine Containing an Adjuvant
Read More
FDA Approvals, In the News
FDA Approves Bridion to Reverse Effects of Neuromuscular Blocking Drugs Used During Surgery
Read More
FDA Approvals, In the News
FDA Approves First Emergency Treatment for Overdose of Certain Types of Chemotherapy
Read More
Page 122 of 244
Results 1211 - 1220 of 2438